title: Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.
abstract: Metrifonate, a pro-drug that is transformed non-enzymatically into a potent inhibitor of acetylcholinesterase (AChE), has been used in the tropics for over 30 years for the treatment of schistosomiasis. A pilot study, and Phase I and Phase II studies of metrifonate in Alzheimer's disease (AD) patients conducted prior to the current study showed benign, dose-dependent adverse event profiles consisting primarily of gastrointestinal events, optimal daily dosing with a loading phase (in the absence of a loading dose phase, 6-8 weeks were required to attain steady-state AChE inhibition levels), and an improvement in Alzheimer's Disease Assessment Scale (ADAS) scores. The current open-label study was designed to evaluate the safety and tolerability of relatively high loading doses, followed by lower maintenance doses of metrifonate in the same patient population, and to determine the maximum tolerated dose (MTD) of metrifonate. Accordingly, the first cohort of 8 probable AD patients (per National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association [NINCDS-ADRDA] criteria) were administered once-daily loading doses of 2.5 mg/kg (125-225 mg) for 14 days, followed by 4.0 mg/kg (200-360 mg) for an additional 3 days. These patients were maintained on once-daily doses of 2.0 mg/kg (100-180 mg) for 14 days. AChE inhibition for this cohort ranged from 88% to 94%. On Day 28 of 31, this cohort was discontinued due to moderate to severe side effects in 6 patients; consequently, the second cohort of 8 probable AD patients received a once-daily loading dose of 2.5 mg/kg (125-225 mg) for 14 days followed by a once-daily maintenance dose of 1.5 mg/kg (75-135 mg) for 35 days. This maintenance dose yielded an AChE inhibition level ranging from 89% to 91%. In spite of an AChE inhibition level comparable to that achieved with the higher dose, the reduced dose was associated with a more favorable adverse event profile which was mainly gastrointestinal and musculoskeletal in nature. The maximum tolerated dose was established at 1.5 mg/kg/day (75-135 mg/day) for maintenance dosing in AD patients.
authors.affiliation: California Clinical Trials, Beverly Hills 90211, USA. ncutler@cctrials.com
authors.forename: N R
authors.initials: NR
authors.lastname: Cutler
authors.forename: S S
authors.initials: SS
authors.lastname: Jhee
authors.forename: P
authors.initials: P
authors.lastname: Cyrus
authors.forename: F
authors.initials: F
authors.lastname: Bieber
authors.forename: P
authors.initials: P
authors.lastname: TanPiengco
authors.forename: J J
authors.initials: JJ
authors.lastname: Sramek
authors.forename: B
authors.initials: B
authors.lastname: Gulanski
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011355:Prodrugs / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014236:Trichlorfon / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000652:urine
chemical_list: D002800:Cholinesterase Inhibitors; D011355:Prodrugs; D014236:Trichlorfon